Companies › Biohaven Pharmaceuticals
2 active drug programs in 2 registered trials: 2 Phase 3; Neurology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| taldefgrobep alfa Engineered IGF-1 analog; recombinant human IGF-1 receptor agonist | IGF1 | Phase 3 | Spinal Muscular Atrophy | Dec 2027 |
| troriluzole Glutamate release inhibitor | – | Phase 3 | Spinocerebellar Ataxias | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03701399 | troriluzole | Phase 3 | Spinocerebellar Ataxias | Neurology | Feb 2022 |
| NCT05337553 | taldefgrobep alfa | Phase 3 | Spinal Muscular Atrophy | Neurology | Dec 2027 |
Cash and short-term investments of $161m on 2026-09-30; operating cash outflow about $459m a year; runway about 4 months at that burn, to Feb 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
–
Annovis Bio Larimar Therapeutics Immunic Alpha Cognition NervGen Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.